帕金森病是常見的神經(jīng)系統(tǒng)變性疾病，凍結(jié)步態(tài)是帕金森病的難治性癥狀，表現(xiàn)為患者試圖行走或前進時步伐短暫、突然地中止，在中晚期帕金森病患者中比較常見，嚴(yán)重影響患者的生活質(zhì)量和預(yù)后。目前帕金森病凍結(jié)步態(tài)的治療以藥物為主，輔以康復(fù)及手術(shù)治療。就帕金森病凍結(jié)步態(tài)治療藥物的研究進展進行綜述，主要包括影響多巴胺能神經(jīng)遞質(zhì)的藥物，如左旋多巴、多巴胺能受體激動劑、單胺氧化酶B抑制劑；同時影響多巴胺能和非多巴胺能神經(jīng)遞質(zhì)的藥物，如金剛烷胺、屈昔多巴聯(lián)合恩他卡朋、哌甲酯等；影響非多巴胺能神經(jīng)遞質(zhì)的藥物，如膽堿酯酶抑制劑、抗抑郁藥及伊曲茶堿等。

Parkinson's disease is a common neurodegenerative disease. Freezing of gait is a refractory symptom of Parkinson's disease, which is manifested by the short and sudden stop of the patient's step when they try to walk or move forward. Freezing of gait is common in the patients with Parkinson's disease in the middle and late stage, which seriously affects the quality of life and prognosis of the patients. At present, the treatment of freezing of gait in Parkinson's disease is mainly drugs, supplemented by rehabilitation and surgery. This paper reviews the research progress of drugs for the treatment of freezing of gait in Parkinson's disease, including drugs that affect dopaminergic neurotransmitters, such as levodopa, dopaminergic receptor agonists, monoamine oxidase B inhibitors; drugs that affect both dopaminergic and non dopaminergic neurotransmitters, such as amantadine, droxidopa combined with entacapone, methylphenidate; drugs that affect nondopaminergic neurotransmitters, such as cholinesterase inhibitors, antidepressants and itracophylline.

R971

國家自然科學(xué)基金面上項目（81471220）；天津市自然科學(xué)基金面上項目（18JCYBJC25900）